SCHEMBL5651975

SCHEMBL5651975

O=C(Nc1ccc(OC(=O)N2CCCCC2)cc1)c1ccc(Cl)nc1

nearest known ligand 0.56

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.56
RAB9A P51151 2/20 0.55
SMN1; SMN2 Q16637 2/20 0.55
ALDH1A1 P00352 3/20 0.52
POLB P06746 1/20 0.52
KMT2A Q03164 2/20 0.52
MITF O75030 1/20 0.52
KCNQ3 O43525 1/20 0.50
KCNQ2 O43526 1/20 0.50
KCNE1 P15382 1/20 0.50
KCNQ1 P51787 1/20 0.50
MEN1 O00255 1/20 0.50
LMNA P02545 1/20 0.50
TSHR P16473 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5649464 0.89 MAPT (0.69) MAPTRAB9ASMN1; SMN2ALDH1A1KMT2A
SCHEMBL5648350 0.78 SMN1; SMN2 (0.64) MAPTRAB9ASMN1; SMN2ALDH1A1POLB
SCHEMBL2302302 0.76 RAB9A (0.72) MAPTRAB9ASMN1; SMN2ALDH1A1POLB
SCHEMBL5651420 0.75 ALDH1A1 (0.64) MAPTRAB9ASMN1; SMN2ALDH1A1POLB
SCHEMBL6631748 0.74 RAB9A (0.64) MAPTRAB9ASMN1; SMN2ALDH1A1KMT2A
SCHEMBL1986996 0.74 KCNQ3 (0.82) MAPTRAB9ASMN1; SMN2ALDH1A1KMT2A
SCHEMBL5215207 0.74 KCNQ3 (0.81) MAPTRAB9ASMN1; SMN2ALDH1A1KMT2A
SCHEMBL5714376 0.74 TNF (0.49) MAPTRAB9ASMN1; SMN2ALDH1A1KMT2A
SCHEMBL5715188 0.73 RAB9A (0.50) MAPTRAB9ASMN1; SMN2KMT2ALMNA
SCHEMBL3313800 0.73 RAB9A (0.75) MAPTRAB9ASMN1; SMN2ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1602191-A Compounds and uses thereof for decreasing activity of hormone-sensitive lipase NOVO NORDISK AS (DK) 2005-03-30 CN claimed
US-20030166644-A1 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase NOVO NORDISK A/S (DK) 2003-09-04 US claimed
US-7279470-B2 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase NOVO NORDISK A/S (DK) 2007-10-09 US disclosed
CN-1326519-C Compounds and uses thereof for decreasing activity of hormone-sensitive lipase NOVO NORDISK AS (DK) 2007-07-18 CN disclosed
US-7067517-B2 Use of compounds for decreasing activity of hormone-sensitive lipase NERO NORDISK A/S (DK) 2006-06-27 US disclosed
CN-1602191-A Compounds and uses thereof for decreasing activity of hormone-sensitive lipase NOVO NORDISK AS (DK) 2005-03-30 CN disclosed
EP-1458375-A2 COMPOSITIONS FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-09-22 EP disclosed
US-20030166644-A1 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase NOVO NORDISK A/S (DK) 2003-09-04 US disclosed
US-20030166690-A1 Use of compounds for decreasing activity of hormone-sensitive NOVO NORDISK A/S (DK) 2003-09-04 US disclosed
WO-2003051842-A2 COMPOSITIONS DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2003-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030166644-A1 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase LIPE, PNLIP, LPL MAPT 4693/4885RAB9A 2926/4885SMN1; SMN2 4233/4885
US-20030166690-A1 Use of compounds for decreasing activity of hormone-sensitive LIPE, PNLIP, LPL MAPT 4668/4885RAB9A 3386/4885SMN1; SMN2 4133/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.